Prevalence of hepatitis B core antibodies with negative hepatitis B surface antigen in dialysis and chronic kidney disease patients

Occult hepatitis B infection (OBI) is a potential cause of infection transmission in patients with chronic kidney disease (CKD) and dialysis-dependant patients. It is liable to be missed since the marker for OBI, hepatitis B core antibody (HBcAb), is not done routinely. We carried out a study to ass...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of kidney diseases and transplantation 2017-07, Vol.28 (4), p.869-873
Main Authors: Tarif, Nauman, Riyad, Muhammad Muhsin, Sabir, Umar, Akhter, Radwan, Rafiq, Kashif, Rizvi, Nabiha
Format: Article
Language:English
Subjects:
Antigens
Blood & organ donations
Care and treatment
Chronic kidney failure
Deoxyribonucleic acid
Developing countries
Disease control
Disease prevention
DNA
Health aspects
Health sciences
Hemodialysis
Hepatitis
Hepatitis B
Hospitals
Infections
Kidney diseases
LDCs
Medicine
Nephrology
Patients
Population
Renal replacement therapy
Studies
Transplants & implants
الأجسام المضادة
الأمراض
التهاب الكبد ب
الكلى
غسيل الكلى
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Occult hepatitis B infection (OBI) is a potential cause of infection transmission in patients with chronic kidney disease (CKD) and dialysis-dependant patients. It is liable to be missed since the marker for OBI, hepatitis B core antibody (HBcAb), is not done routinely. We carried out a study to assess the prevalence of OBI in CKD Stage II–V or requiring renal replacement therapy. It was a cross-sectional study carried out at Fatima Memorial Hospital, Lahore, from May 2104 to May 2015. A total of 188 patients were included in this study, 124 were dialysis dependent and 64 had acute or CKD Stage II–V. About 17.55% (n = 33) of patients had isolated HBcAb positive. Nearly 33.5% (n = 63) of patients were found to have hepatitis B surface antigen positive, indicating development of immunity by exposure to virus. About 20.74% (n = 39) of patients were co-positive with HBcAb also. The prevalence of isolated HBcAb in dialysis and CKD patients is high; therefore, testing for HBcAb should be a routine part of screening in our CKD population to rule out OBI. Further confirmation with polymerase chain reaction analysis for HBV viral DNA is recommended. Considering our circumstances, a consensus statement from the hepatologists and nephrologists is needed to further plan for the management of such cases
ISSN:1319-2442
2320-3838